Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

ICAM1 expression is induced by proinflammatory cytokines and associated with TLS formation in aggressive breast cancer subtypes.

Figenschau SL, Knutsen E, Urbarova I, Fenton C, Elston B, Perander M, Mortensen ES, Fenton KA.

Sci Rep. 2018 Aug 6;8(1):11720. doi: 10.1038/s41598-018-29604-2.

2.

Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret (Mustela putorius furo).

Cross RW, Mire CE, Agans KN, Borisevich V, Fenton KA, Geisbert TW.

J Infect Dis. 2018 Jun 28. doi: 10.1093/infdis/jiy268. [Epub ahead of print]

PMID:
29955887
3.

Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates.

Woolsey C, Geisbert JB, Matassov D, Agans KN, Borisevich V, Cross RW, Deer DJ, Fenton KA, Eldridge JH, Mire CE, Geisbert TW.

J Infect Dis. 2018 Jun 25. doi: 10.1093/infdis/jiy293. [Epub ahead of print]

PMID:
29939296
4.

Mesenchymal stem cells and T cells in the formation of Tertiary Lymphoid Structures in Lupus Nephritis.

Dorraji SE, Hovd AK, Kanapathippillai P, Bakland G, Eilertsen GØ, Figenschau SL, Fenton KA.

Sci Rep. 2018 May 18;8(1):7861. doi: 10.1038/s41598-018-26265-z.

5.

Putting the public (back) into public health: leadership, evidence and action.

South J, Connolly AM, Stansfield JA, Johnstone P, Henderson G, Fenton KA.

J Public Health (Oxf). 2018 Mar 13. doi: 10.1093/pubmed/fdy041. [Epub ahead of print]

PMID:
29546426
6.

Innovation challenge contests to enhance HIV responses.

Tucker JD, Fenton KA.

Lancet HIV. 2018 Mar;5(3):e113-e115. doi: 10.1016/S2352-3018(18)30027-4. No abstract available.

PMID:
29519613
7.

The HepTestContest: a global innovation contest to identify approaches to hepatitis B and C testing.

Tucker JD, Meyers K, Best J, Kaplan K, Pendse R, Fenton KA, Andrieux-Meyer I, Figueroa C, Goicochea P, Gore C, Ishizaki A, Khwairakpam G, Miller V, Mozalevskis A, Ninburg M, Ocama P, Peeling R, Walsh N, Colombo MG, Easterbrook P.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):701. doi: 10.1186/s12879-017-2771-4.

8.

siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease.

Thi EP, Mire CE, Lee AC, Geisbert JB, Ursic-Bedoya R, Agans KN, Robbins M, Deer DJ, Cross RW, Kondratowicz AS, Fenton KA, MacLachlan I, Geisbert TW.

J Clin Invest. 2017 Dec 1;127(12):4437-4448. doi: 10.1172/JCI96185. Epub 2017 Nov 6.

9.

Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.

Mire CE, Cross RW, Geisbert JB, Borisevich V, Agans KN, Deer DJ, Heinrich ML, Rowland MM, Goba A, Momoh M, Boisen ML, Grant DS, Fullah M, Khan SH, Fenton KA, Robinson JE, Branco LM, Garry RF, Geisbert TW.

Nat Med. 2017 Oct;23(10):1146-1149. doi: 10.1038/nm.4396. Epub 2017 Sep 4.

10.

Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.

Mire CE, Geisbert JB, Borisevich V, Fenton KA, Agans KN, Flyak AI, Deer DJ, Steinkellner H, Bohorov O, Bohorova N, Goodman C, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Crowe JE Jr, Zeitlin L, Geisbert TW.

Sci Transl Med. 2017 Apr 5;9(384). pii: eaai8711. doi: 10.1126/scitranslmed.aai8711.

11.

Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA.

Thi EP, Lee AC, Geisbert JB, Ursic-Bedoya R, Agans KN, Robbins M, Deer DJ, Fenton KA, Kondratowicz AS, MacLachlan I, Geisbert TW, Mire CE.

Nat Microbiol. 2016 Aug 22;1(10):16142. doi: 10.1038/nmicrobiol.2016.142.

12.

Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates.

Mire CE, Geisbert JB, Agans KN, Thi EP, Lee AC, Fenton KA, Geisbert TW.

J Infect Dis. 2016 Oct 15;214(suppl 3):S367-S374. Epub 2016 Aug 28.

13.

Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy.

Mire CE, Satterfield BA, Geisbert JB, Agans KN, Borisevich V, Yan L, Chan YP, Cross RW, Fenton KA, Broder CC, Geisbert TW.

Sci Rep. 2016 Aug 3;6:30916. doi: 10.1038/srep30916.

14.

The Domestic Ferret (Mustela putorius furo) as a Lethal Infection Model for 3 Species of Ebolavirus.

Cross RW, Mire CE, Borisevich V, Geisbert JB, Fenton KA, Geisbert TW.

J Infect Dis. 2016 Aug 15;214(4):565-9. doi: 10.1093/infdis/jiw209. Epub 2016 May 24.

15.

Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus.

Mire CE, Geisbert JB, Agans KN, Deer DJ, Fenton KA, Geisbert TW.

J Infect Dis. 2016 Oct 15;214(suppl 3):S263-S267. Epub 2016 Jun 9.

16.

Nipah Virus C and W Proteins Contribute to Respiratory Disease in Ferrets.

Satterfield BA, Cross RW, Fenton KA, Borisevich V, Agans KN, Deer DJ, Graber J, Basler CF, Geisbert TW, Mire CE.

J Virol. 2016 Jun 24;90(14):6326-6343. doi: 10.1128/JVI.00215-16. Print 2016 Jul 15.

17.

Monoclonal antibody therapy for Junin virus infection.

Zeitlin L, Geisbert JB, Deer DJ, Fenton KA, Bohorov O, Bohorova N, Goodman C, Kim D, Hiatt A, Pauly MH, Velasco J, Whaley KJ, Altmann F, Gruber C, Steinkellner H, Honko AN, Kuehne AI, Aman MJ, Sahandi S, Enterlein S, Zhan X, Enria D, Geisbert TW.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4458-63. doi: 10.1073/pnas.1600996113. Epub 2016 Apr 4.

18.

Surveillance systems for sexually transmitted infections: a global review.

Mohammed H, Hughes G, Fenton KA.

Curr Opin Infect Dis. 2016 Feb;29(1):64-9. doi: 10.1097/QCO.0000000000000235. Review.

PMID:
26658655
19.

Changes in health in England, with analysis by English regions and areas of deprivation, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Newton JN, Briggs AD, Murray CJ, Dicker D, Foreman KJ, Wang H, Naghavi M, Forouzanfar MH, Ohno SL, Barber RM, Vos T, Stanaway JD, Schmidt JC, Hughes AJ, Fay DF, Ecob R, Gresser C, McKee M, Rutter H, Abubakar I, Ali R, Anderson HR, Banerjee A, Bennett DA, Bernabé E, Bhui KS, Biryukov SM, Bourne RR, Brayne CE, Bruce NG, Brugha TS, Burch M, Capewell S, Casey D, Chowdhury R, Coates MM, Cooper C, Critchley JA, Dargan PI, Dherani MK, Elliott P, Ezzati M, Fenton KA, Fraser MS, Fürst T, Greaves F, Green MA, Gunnell DJ, Hannigan BM, Hay RJ, Hay SI, Hemingway H, Larson HJ, Looker KJ, Lunevicius R, Lyons RA, Marcenes W, Mason-Jones AJ, Matthews FE, Moller H, Murdoch ME, Newton CR, Pearce N, Piel FB, Pope D, Rahimi K, Rodriguez A, Scarborough P, Schumacher AE, Shiue I, Smeeth L, Tedstone A, Valabhji J, Williams HC, Wolfe CD, Woolf AD, Davis AC.

Lancet. 2015 Dec 5;386(10010):2257-74. doi: 10.1016/S0140-6736(15)00195-6. Epub 2015 Sep 14.

20.

Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.

Meyer M, Garron T, Lubaki NM, Mire CE, Fenton KA, Klages C, Olinger GG, Geisbert TW, Collins PL, Bukreyev A.

J Clin Invest. 2015 Aug 3;125(8):3241-55. doi: 10.1172/JCI81532. Epub 2015 Jul 13.

21.

The immunomodulating V and W proteins of Nipah virus determine disease course.

Satterfield BA, Cross RW, Fenton KA, Agans KN, Basler CF, Geisbert TW, Mire CE.

Nat Commun. 2015 Jun 24;6:7483. doi: 10.1038/ncomms8483.

22.

Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig Model.

Cross RW, Fenton KA, Geisbert JB, Ebihara H, Mire CE, Geisbert TW.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S258-70. doi: 10.1093/infdis/jiv182. Epub 2015 Jun 19.

23.

Modeling the Disease Course of Zaire ebolavirus Infection in the Outbred Guinea Pig.

Cross RW, Fenton KA, Geisbert JB, Mire CE, Geisbert TW.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S305-15. doi: 10.1093/infdis/jiv237. Epub 2015 Jun 2.

PMID:
26038397
24.

Response to Capewell et al.

Waterall J, Greaves F, Gresser C, Kearney M, Fenton KA.

J Public Health (Oxf). 2015 Jun;37(2):193-4. doi: 10.1093/pubmed/fdv065. No abstract available.

PMID:
26022811
25.

NHS Health Check: an innovative component of local adult health improvement and well-being programmes in England.

Waterall J, Greaves F, Kearney M, Fenton KA.

J Public Health (Oxf). 2015 Jun;37(2):177-84. doi: 10.1093/pubmed/fdv062. No abstract available.

PMID:
26022808
26.

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

Thi EP, Mire CE, Lee AC, Geisbert JB, Zhou JZ, Agans KN, Snead NM, Deer DJ, Barnard TR, Fenton KA, MacLachlan I, Geisbert TW.

Nature. 2015 May 21;521(7552):362-5. doi: 10.1038/nature14442. Epub 2015 Apr 22.

27.

Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients.

Figenschau SL, Fismen S, Fenton KA, Fenton C, Mortensen ES.

BMC Cancer. 2015 Mar 6;15:101. doi: 10.1186/s12885-015-1116-1.

28.

Tackling High Blood Pressure in England: A New Approach.

Lumley B, Waterall J, Kearney M, Fenton KA.

J Clin Hypertens (Greenwich). 2015 Aug;17(8):575-7. doi: 10.1111/jch.12548. Epub 2015 Apr 9. No abstract available.

29.

Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.

Mire CE, Matassov D, Geisbert JB, Latham TE, Agans KN, Xu R, Ota-Setlik A, Egan MA, Fenton KA, Clarke DK, Eldridge JH, Geisbert TW.

Nature. 2015 Apr 30;520(7549):688-691. doi: 10.1038/nature14428. Epub 2015 Apr 8.

30.

Lack of Marburg Virus Transmission From Experimentally Infected to Susceptible In-Contact Egyptian Fruit Bats.

Paweska JT, Jansen van Vuren P, Fenton KA, Graves K, Grobbelaar AA, Moolla N, Leman P, Weyer J, Storm N, McCulloch SD, Scott TP, Markotter W, Odendaal L, Clift SJ, Geisbert TW, Hale MJ, Kemp A.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S109-18. doi: 10.1093/infdis/jiv132. Epub 2015 Apr 2.

PMID:
25838270
31.

The status quo is not an evidence-based option.

Kearney M, Waterall J, Greaves F, Fenton KA.

Br J Gen Pract. 2015 Feb;65(631):61. doi: 10.3399/bjgp15X683401. No abstract available.

32.

A strategic approach to public health workforce development and capacity building.

Dean HD, Myles RL, Spears-Jones C, Bishop-Cline A, Fenton KA.

Am J Prev Med. 2014 Nov;47(5 Suppl 3):S288-96. doi: 10.1016/j.amepre.2014.07.016. Epub 2014 Oct 16.

33.

Hepatitis - a devastating epidemic in Europe.

Lazarus JV, Fenton KA.

BMC Infect Dis. 2014;14 Suppl 6:S1. doi: 10.1186/1471-2334-14-S6-S1. Epub 2014 Sep 19. No abstract available.

34.

Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA.

Thi EP, Mire CE, Ursic-Bedoya R, Geisbert JB, Lee ACH, Agans KN, Robbins M, Deer DJ, Fenton KA, MacLachlan I, Geisbert TW.

Sci Transl Med. 2014 Aug 20;6(250):250ra116. doi: 10.1126/scitranslmed.3009706.

35.

NHS Health Check programme: too early to conclude.

Newton JN, Davis A, Waterall J, Fenton KA.

BMJ. 2014 Jul 30;349:g4785. doi: 10.1136/bmj.g4785. No abstract available.

PMID:
25078427
36.

Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody.

Geisbert TW, Mire CE, Geisbert JB, Chan YP, Agans KN, Feldmann F, Fenton KA, Zhu Z, Dimitrov DS, Scott DP, Bossart KN, Feldmann H, Broder CC.

Sci Transl Med. 2014 Jun 25;6(242):242ra82. doi: 10.1126/scitranslmed.3008929.

37.

A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge.

Mire CE, Geisbert JB, Agans KN, Feng YR, Fenton KA, Bossart KN, Yan L, Chan YP, Broder CC, Geisbert TW.

J Virol. 2014 May;88(9):4624-31. doi: 10.1128/JVI.00005-14. Epub 2014 Feb 12.

38.
39.

Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease.

Mire CE, Versteeg KM, Cross RW, Agans KN, Fenton KA, Whitt MA, Geisbert TW.

Virol J. 2013 Dec 13;10:353. doi: 10.1186/1743-422X-10-353.

40.

HIV in the UK: test, test, and test again.

Nardone A, Delpech V, Gill ON, Fenton KA, Anderson J.

Lancet. 2013 Nov 23;382(9906):1687-8. doi: 10.1016/S0140-6736(13)62377-6. No abstract available.

PMID:
24267988
42.

From theory to action: applying social determinants of health to public health practice.

Dean HD, Williams KM, Fenton KA.

Public Health Rep. 2013 Nov;128 Suppl 3:1-4. No abstract available.

43.

LMW heparin prevents increased kidney expression of proinflammatory mediators in (NZBxNZW)F1 mice.

Hedberg A, Kanapathippillai P, Rekvig OP, Fenton KA.

Clin Dev Immunol. 2013;2013:791262. doi: 10.1155/2013/791262. Epub 2013 Sep 17.

44.

Program collaboration and service integration: implementation successes and challenges.

Fenton KA, Steiner RJ.

Sex Transm Dis. 2013 Aug;40(8):675-7. doi: 10.1097/OLQ.0000000000000003. No abstract available.

PMID:
23859919
45.
46.

UK health performance: findings of the Global Burden of Disease Study 2010.

Murray CJ, Richards MA, Newton JN, Fenton KA, Anderson HR, Atkinson C, Bennett D, Bernabé E, Blencowe H, Bourne R, Braithwaite T, Brayne C, Bruce NG, Brugha TS, Burney P, Dherani M, Dolk H, Edmond K, Ezzati M, Flaxman AD, Fleming TD, Freedman G, Gunnell D, Hay RJ, Hutchings SJ, Ohno SL, Lozano R, Lyons RA, Marcenes W, Naghavi M, Newton CR, Pearce N, Pope D, Rushton L, Salomon JA, Shibuya K, Vos T, Wang H, Williams HC, Woolf AD, Lopez AD, Davis A.

Lancet. 2013 Mar 23;381(9871):997-1020. doi: 10.1016/S0140-6736(13)60355-4. Epub 2013 Mar 5.

PMID:
23668584
47.

Nucleosomes contribute to increase mesangial cell chemokine expression during the development of lupus nephritis.

Kanapathippillai P, Hedberg A, Fenton CG, Fenton KA.

Cytokine. 2013 May;62(2):244-52. doi: 10.1016/j.cyto.2013.03.016. Epub 2013 Apr 4.

PMID:
23561928
48.

Considerations for national public health leadership in advancing sexual health.

Ivankovich MB, Fenton KA, Douglas JM Jr.

Public Health Rep. 2013 Mar-Apr;128 Suppl 1:102-10.

49.

Understanding sexual health and its role in more effective prevention programs.

Douglas JM Jr, Fenton KA.

Public Health Rep. 2013 Mar-Apr;128 Suppl 1:1-4. No abstract available.

50.

The future of HIV prevention in the United States.

Mermin J, Fenton KA.

JAMA. 2012 Jul 25;308(4):347-8. doi: 10.1001/jama.2012.8693. No abstract available.

PMID:
22820785

Supplemental Content

Loading ...
Support Center